Novozymes and Prometic Enter Into Alliance for Purification of Albumin-Fusion Proteins
News Feb 05, 2010
Novozymes and ProMetic Life Sciences Inc. have announced that they have entered into a strategic alliance regarding proprietary albumin purification technology based upon a synthetic-ligand affinity adsorbent developed by ProMetic’s UK subsidiary, ProMetic BioSciences Ltd. The purification technology has been designed for the rapid development of Novozymes’ albufuse® albumin-fusion molecules.
Under the terms of the co-marketing alliance the companies will jointly promote the use of a new synthetic-ligand affinity adsorbent, marketed under the trade-name AlbuPure®, as a platform approach for the purification of albumin and albumin-fusion proteins.
ProMetic will be the exclusive manufacturer and supplier of AlbuPure®, however both parties will retain ownership of their respective technologies and both Novozymes and ProMetic will have the right to market AlbuPure®.
ProMetic and Novozymes Biopharma, a subsidiary of Novozymes, have collaborated on the development of AlbuPure® which was derived from ProMetic’s Mimetic Ligand™ technology and targeted at the capture and purification of recombinant albumin proteins produced in yeast. AlbuPure® binds specifically to the albumin portion of the molecule and so can be used for the purification of any albufuse® albumin-fusion protein.
Two proteins that activate the fastest molecule in our nerve cells have been identified by researchers at University of Warwick. This mechanism is responsible for transport through our nervous system. This finding could lead to a new therapeutic treatments for people with hereditary spastic paraplegia and other neurological disorders.READ MORE